YXYingqi Xu

Yingqi Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yingqi Xu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends and outcomes of COVID-19 hospital admissions “for” vs “with” COVID-19 in Singapore: A retrospective cohort study using the SingHealth COVID-19 registry

    by Yingqi Xu, Ee Chern Kwek, Keith Ee Gene Teo, Edwin Philip Conceicao, Jean Xiang Ying Sim, Shalvi Arora, Indumathi Venkatachalam, Sze Ling Chan

  • Open Access

    Relationship between anti-diabetic medication use and glycaemic control: a retrospective diabetes registry-based cohort study in Singapore

    by Sze Ling Chan, Charyl Jia Qi Yap, Yingqi Xu, Sing Yi Chia, Nur Nasyitah Binte Mohamed Salim, Darryl Mingjun Lim, Edward Choke, David Carmody, Gilbert Choon Seng Tan, Su-Yen Goh, et al.

    Objective: This study aimed to determine the association between diabetes mellitus (DM) medication use and glycaemic control. Design: This was a retrospective diabetes registry-based cohort study. Setting: Singapore. Participants: Patients aged 18 and above with incident DM in the SingHealth Diabetes Registry from 2013 to 2020 were included. The entire study period included a 1 year baseline period, a 1 year observation period and a 3 month outcome period. Outcome measures: Drug use was measured using the proportion of days covered (PDC), and the changes in glycated haemoglobin (HbA1c) between the outcome and baseline periods were assessed. The associations between baseline HbA1c and PDC ≥0.80 and between PDC and change in HbA1c were analysed using logistic regression and the Kruskal–Wallis test, respectively. Results: Of 184 646 unique patients in the registry from 2013 to 2020, 36 314 met the inclusion and exclusion criteria and were included in the analysis. The median PDC for any DM drug, oral DM drugs and insulin during the observation period was 20.3%, 16.8% and 0%, respectively. Those who had good glycaemic control at baseline were less likely to receive DM drugs and those with poor baseline glycaemic control or missing baseline HbA1c were more likely to be consistent users (PDC >80%) (p-16). Conclusion: The relationship between DM drug use and glycaemic control is complex and non-monotonic. Higher PDC for any DM drug and oral DM drugs during the observation period was significantly associated with clinically relevant HbA1c improvements.


  • Impact of team‐based pharmaceutical care on the humanistic outcomes among patients with long‐standing diabetes: An interim analysis of a randomized, controlled, multicenter study

    by Yingqi Xu, Paul J. Gallagher, Cheryl W. Y. Tan, Keith Y. K. Tsou, David H. Y. Tan, Henry Ramaya, Joyce Y.‐C. Lee

    Introduction: Epidemiological studies have reported that diabetes‐related complications increase after 5 years of uncontrolled/suboptimal metabolic control. The risk of experiencing diabetes‐related microvascular diseases usually spike after 10 years of uncontrolled diabetes.Objectives: The objective of this study was to evaluate the impact of team‐based pharmaceutical care on glycemic control, self‐care, diabetes‐dependent quality of life, and productivity loss in patients with long‐standing diabetes (≥5 years).Methods: This was a prospective, multicenter, randomized, controlled study. Patients with a glycosylated hemoglobin (HbA1c) > 7%, long‐standing diabetes defined as having a disease duration of at least 5 years, and polypharmacy defined as taking 5 or more chronic medications were included in the study. Patients in the intervention arm received team‐based pharmaceutical care regularly while patients in the control arm received physician‐centered care. Patients' humanistic outcomes were followed for 6 months.Results: A total of 248 patients (126 intervention and 122 control) were included in the study. In addition to improved glycemic control observed in the intervention arm (mean difference: 0.44%, P = .003, 95% confidence interval: [0.15, 0.73]), the intervention arm showed significant improvements in overall self‐care level (+0.36, 95% confidence interval: [0.01, 0.72], P = .045) and self‐monitoring of blood glucose (+1.87, 95% confidence interval: [1.00, 2.99], P < .001) compared with the control arm. There were no significant differences in the changes in diabetes‐associated quality of life and overall work impairment between the two arms. A significant difference in activity impairment (affected productivity in regular unpaid activity) between the two arms was found, with 43.3% impairment having occurred in the control group vs 27.9% in the intervention group (P = .047).Conclusion: Team‐based pharmaceutical care significantly improved overall self‐care and glycemia without deteriorating quality of life and incurring productivity loss. Our findings highlighted the value of team‐based pharmaceutical care in managing diabetes‐experienced patients.


  • Evaluating the impact of self‐monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta‐analysis

    by Yingqi Xu, David Hsien Yung Tan, Joyce Yu‐Chia Lee

    Aims International diabetes guidelines have not established the frequencies of self‐monitoring of blood glucose in patients with type 2 diabetes (T2D) who do not use insulin. The present study aimed to assess the impact of SMBG frequencies on the glucose control and other outcomes in non‐insulin‐treated patients with T2D. Methods A literature search was performed in four databases. Randomised controlled trials with ≥ 6‐month follow‐up duration that compared the impact of different frequencies of SMBG on glycated haemoglobin A1c (HbA1c) were included. Studies with abstract only or reported effects of SMBG as a secondary outcome were excluded. Results Of the 1,557 studies identified, 12 RCTs with a total of 3,350 patients were analyzed. Overall, performing SMBG for 8 to 14 times per week was correlated with a better HbA1c control at six months (MD ‐0.46%, 95% CI ‐0.54 to ‐0.39) and 12 months (MD ‐0.20%, 95% CI ‐0.29 to ‐0.11). However, up to seven measurements of SMBG per week did not significantly affect glycemic control. In addition, performing SMBG between 8 and 14 times per week was also associated with improved BMI (MD ‐0.46, 95% CI ‐0.84 to ‐0.08). When the results of SMBG were applied to adjust diabetes medication, a significant reduction in HbA1c levels was observed in the intervention arm compared to the control arm. Conclusions 8 to 14 measurements of SMBG per week were associated with an improved glycemic control and a reduced BMI in patients with T2D not using insulin.